Literature DB >> 10704163

Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

S M Haffner1, L Mykkänen, A Festa, J P Burke, M P Stern.   

Abstract

BACKGROUND: Subjects who convert to type 2 diabetes mellitus have increased cardiovascular risk factors relative to nonconverters. However, it is not known whether these atherogenic changes in the prediabetic state are predominantly due to insulin resistance, decreased insulin secretion, or both. METHODS AND
RESULTS: We examined this issue in the 7-year follow-up of the San Antonio Heart Study, in which 195 of 1734 subjects converted to type 2 diabetes. At baseline, converters had significantly higher body mass index, waist circumference, triglyceride concentration, and blood pressure and lower HDL cholesterol than nonconverters. Atherogenic changes in converters were markedly attenuated (and no longer significant) after adjustment for the homeostasis model assessment of insulin resistance (HOMA IR, a surrogate for insulin resistance); in contrast, the differences in risk factors between converters and nonconverters increased after adjustment for the ratio of early insulin increment to early glucose increment (DeltaI(30-0)/DeltaG(30-0)) during an oral glucose tolerance test (a surrogate for insulin secretion). We also compared converters who had a predominant insulin resistance (high HOMA IR and high DeltaI(30-0)/DeltaG(30-0)) (n=56) and converters who had a predominant decrease in insulin secretion (low HOMA IR and low DeltaI(30-0)/DeltaG(30-0)) (n=31) with nonconverters (n=1539). Only the converters who were insulin resistant had higher blood pressure and triglyceride levels and lower HDL cholesterol levels than nonconverters.
CONCLUSIONS: Our data suggest that atherogenic changes in the prediabetic state are mainly seen in insulin-resistant subjects and that strategies to prevent type 2 diabetes might focus on insulin-sensitizing interventions rather than interventions that increase insulin secretion because of potential effects on cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704163     DOI: 10.1161/01.cir.101.9.975

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  84 in total

1.  Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus : an open, multicentre, observational study.

Authors:  Thomas Konrad; Georg Lübben; Christine Franzen
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease.

Authors:  C D A Stehouwer; R M A Henry; I Ferreira
Journal:  Diabetologia       Date:  2008-02-01       Impact factor: 10.122

Review 3.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

Review 4.  Prediabetes mellitus and its links to atherosclerosis.

Authors:  Daniel Kramer; Annaswamy Raji; Jorge Plutzky
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

Review 5.  Epidemiology of the insulin resistance syndrome.

Authors:  James B Meigs
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

Review 6.  The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  R Kahn; J Buse; E Ferrannini; M Stern
Journal:  Diabetologia       Date:  2005-09       Impact factor: 10.122

7.  Short term follow-up of prediabetics undergoing elective percutaneous coronary intervention.

Authors:  W El-Hammady; A Shawky; A El-Annany
Journal:  J Saudi Heart Assoc       Date:  2013-01-26

Review 8.  Should the insulin resistance syndrome be treated in the elderly?

Authors:  Richard W Grant; James B Meigs
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Silent myocardial ischemia in prediabetics in relation to insulin resistance.

Authors:  Gamela Nasr; Hamdy Sliem
Journal:  J Cardiovasc Dis Res       Date:  2010-07

10.  Is prehypertension a risk factor for the development of type 2 diabetes?

Authors:  David R Mullican; Carlos Lorenzo; Steven M Haffner
Journal:  Diabetes Care       Date:  2009-07-23       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.